Earnings summaries and quarterly performance for PACIFIC BIOSCIENCES OF CALIFORNIA.
Executive leadership at PACIFIC BIOSCIENCES OF CALIFORNIA.
Board of directors at PACIFIC BIOSCIENCES OF CALIFORNIA.
Research analysts who have asked questions during PACIFIC BIOSCIENCES OF CALIFORNIA earnings calls.
Jack Meehan
Nephron Research LLC
6 questions for PACB
Also covers: A, AVTR, BIO +18 more
MC
Mason Carrico
Stephens Inc.
5 questions for PACB
Also covers: AKYA, CDNA, CSTL +13 more
David Westenberg
Piper Sandler
4 questions for PACB
Also covers: ADPT, AKYA, BLLN +14 more
KM
Kyle Mikson
Canaccord Genuity
3 questions for PACB
Also covers: AKYA, BDSX, CAI +13 more
Subbu Nambi
Guggenheim Securities
3 questions for PACB
Also covers: ADPT, BLLN, BOLD +23 more
Tycho Peterson
Jefferies
3 questions for PACB
Also covers: A, AVTR, BIO +22 more
DB
Dan Brennan
UBS
2 questions for PACB
Also covers: A, ADPT, AVTR +17 more
Daniel Brennan
TD Cowen
2 questions for PACB
Also covers: A, ADPT, AVTR +25 more
DS
Doug Shenko
Wolfe Research
2 questions for PACB
KM
Kyle Mixon
Cantor
2 questions for PACB
Also covers: GRAL, TXG
SN
Subhalaxmi Nambi
Guggenheim Securities
2 questions for PACB
Also covers: AKYA, BRKR, CSTL +15 more
TS
Tejas Savant
Morgan Stanley
2 questions for PACB
Also covers: ADPT, AKYA, AVTR +20 more
AA
Alex Aylen
Canaccord Genuity
1 question for PACB
Douglas Schenkel
Wolfe Research, LLC
1 question for PACB
Also covers: A, AVTR, BRKR +21 more
Doug Schenkel
Wolfe Research LLC
1 question for PACB
Also covers: A, AVTR, BRKR +19 more
EB
Eve Burstein
Goldman Sachs
1 question for PACB
Also covers: EXAS, GH, ILMN +1 more
Harrison Parsons
Stephens
1 question for PACB
Also covers: CTKB, CUTR, HOLX
JA
Jake Allen
Goldman Sachs
1 question for PACB
Also covers: QTRX
L
Lauren
Jefferies Financial Group Inc.
1 question for PACB
Also covers: NEO, TXG
Luke Sergott
Barclays
1 question for PACB
Also covers: A, AVTR, BRKR +20 more
Madeline Mollman
Wolfe Research, LLC
1 question for PACB
Also covers: MRVI, TWST, TXG
MP
Matthew Park
Cantor Fitzgerald
1 question for PACB
Also covers: AXGN, BVS, CERS +5 more
Salem Salem
Barclays
1 question for PACB
Also covers: GH, IQV, QGEN +3 more
SJ
Sung Ji Nam
Scotiabank
1 question for PACB
Also covers: ADPT, BDSX, BNGO +9 more
TS
Tom Stevens
Cowen and Company
1 question for PACB
Also covers: PSNL
WR
William Ruby
TD Cowen
1 question for PACB
Also covers: BDSX, PSNL, SERA +1 more
YO
Yuko Oku
Morgan Stanley
1 question for PACB
Also covers: ADPT, GH, GRAL +7 more
Recent press releases and 8-K filings for PACB.
Pacific Biosciences of California Announces Executive Change and Litigation Settlement
PACB
Management Change
Legal Proceedings
- Michele Farmer notified Pacific Biosciences of California, Inc. (PACB) of her voluntary resignation as Chief Accounting Officer, effective March 21, 2026.
- Jim R. Gibson, PACB's Chief Financial Officer, will assume the role of principal accounting officer upon Ms. Farmer's resignation.
- On March 5, 2026, PACB entered into a binding term sheet with Personal Genomics of Taiwan, Inc. (PGI) to amicably resolve litigation.
- The settlement grants PACB a worldwide, royalty-free, non-exclusive license under a U.S. patent and a five-and-a-half-year covenant not to sue under PGI's patents.
- PACB will pay PGI $8,000,000 in the first quarter of 2026, and $5,000,000 in the first quarter of each of 2027, 2028, and 2029, with potential additional payments in 2027 based on 2026 revenue targets.
7 days ago
Pacific Biosciences Discusses 2026 Outlook, SPARQ-Nx Chemistry, and Clinical Growth at TD Cowen Conference
PACB
Product Launch
Guidance Update
New Projects/Investments
- Pacific Biosciences is rolling out its SPARQ-Nx chemistry in early summer/late spring 2026, which is expected to dramatically lower the price per genome to sub $300 for 10,000 samples and in the $200 range or less for 50,000 samples, while also being accretive to gross margins.
- The company improved gross margins by 700 basis points in 2025 and expects further improvement of 100 to 400 basis points in 2026, driving towards profitability through decreasing costs and accelerating revenue growth.
- Clinical consumables shipments grew 55% in 2025 and are expected to continue growing in 2026, with the CEO projecting the clinical business could be over half of total business in five years. In contrast, the U.S. academic market was challenging in 2025 and is expected to remain conservative in 2026.
- Pacific Biosciences asserts a strong competitive position with its unique long-read, single-molecule sequencing technology, which offers higher accuracy and the ability to see epigenetics, distinguishing it from competitors like Illumina's TruPath.
Mar 2, 2026, 7:30 PM
Pacific Biosciences Discusses 2026 Outlook, New Product Rollout, and Clinical Business Growth
PACB
Product Launch
Guidance Update
Revenue Acceleration/Inflection
- Pacific Biosciences is rolling out its SPRQ-Nx chemistry in 2026, enabling significantly lower per-genome pricing (e.g., sub $300 for 10,000 samples, $200 range or less for 50,000 samples) and is expected to be accretive to gross margins.
- The clinical business grew 55% in consumables in 2025 and is projected to continue growing in 2026, with the potential to comprise over half of the total business in five years.
- Gross margins improved by 700 basis points in 2025, with an additional 100 to 400 basis points of improvement guided for 2026.
- The U.S. academic market faced challenges in 2025, resulting in a $30 million hole, and is expected to remain conservative in 2026, with growth primarily driven by international markets and the clinical segment.
Mar 2, 2026, 7:30 PM
Pacific Biosciences Discusses 2026 Outlook, New Chemistry, and Clinical Market Expansion
PACB
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- Pacific Biosciences is rolling out its SPRQ-Nx chemistry in 2026, a breakthrough product offering better performance, increased throughput, and dramatically lower per-sample costs due to SMRT Cell reuse, making it competitive with short-read sequencing.
- The company's clinical business grew 55% in 2025 (consumables) and is expected to continue accelerating, with potential to become over half of total revenue in five years. Key clinical applications include rare disease, carrier testing, and newborn screening.
- Gross margins improved by 700 basis points in 2025 and are projected to improve by an additional 100 to 400 basis points in 2026, driven by the new chemistry and increased utilization.
- The U.S. academic market remains challenging for 2026, with growth anticipated from international markets, particularly Europe, and the expanding clinical customer segment.
Mar 2, 2026, 7:30 PM
PacBio Reports Strong Q4 2025 Results and Provides 2026 Guidance
PACB
Earnings
Guidance Update
Revenue Acceleration/Inflection
- PacBio reported Q4 2025 revenue of $44.6 million, a 14% year-over-year increase, driven by record consumable revenue and strong instrument placements.
- For the full year 2025, total revenue reached $160 million, growing 4% over 2024, with consumables revenue increasing 16% to $82 million.
- Non-GAAP gross margin significantly improved to 40% in both Q4 and full year 2025, up from 31% and 33% respectively in 2024.
- The company provided 2026 revenue guidance in the range of $165 million to $180 million, representing approximately 8% growth at the midpoint, and expects a 100-400 basis point improvement in non-GAAP gross margin.
- Strategic focus remains on accelerating clinical adoption, supported by the upcoming launch of SparkNex chemistry, while anticipating a continued muted academic funding environment.
Feb 12, 2026, 10:00 PM
Pacific Biosciences Reports Q4 and Full-Year 2025 Results, Provides 2026 Guidance
PACB
Earnings
Guidance Update
Product Launch
- Pacific Biosciences reported Q4 2025 revenue of $44.6 million, a 14% year-over-year increase, contributing to a full-year 2025 revenue of $160 million, up 4% from 2024.
- The company provided 2026 revenue guidance of $165 million to $180 million, representing approximately 8% growth at the midpoint, primarily driven by consumables and an expanding instrument installed base.
- Financial profile improvements include a non-GAAP gross margin increase to 40% in 2025 (from 27% in 2023) and a reduction in non-GAAP operating expenses to $230 million in 2025 (from $355 million in 2023). Cash burn also improved to $105 million in 2025 from $214 million in 2023, with $279.5 million in cash and investments at year-end.
- Strategic moves include the sale of short-read sequencing assets for $48 million and the upcoming 2026 launch of SparkNex, a new consumable chemistry designed to deliver HiFi sequencing for less than $300 per genome with 25% higher throughput.
Feb 12, 2026, 10:00 PM
PacBio Reports Strong Q4 and Full-Year 2025 Results, Provides 2026 Guidance
PACB
Earnings
Guidance Update
Revenue Acceleration/Inflection
- PacBio reported Q4 2025 total revenue of $44.6 million and full-year 2025 total revenue of $160.0 million, driven by record consumables revenue and 55% consumables growth for clinical and hospital customers in FY 2025.
- The company significantly improved its financial profile in 2025, with Non-GAAP Gross Margin reaching 40%, Non-GAAP Operating Expenses reduced to $230 million, and Adjusted Cash Burn improved to $(105 million).
- PacBio strengthened its balance sheet and sharpened its focus on long-read sequencing by selling its short-read sequencing assets, which generated approximately $48 million in net proceeds. Cash and investments stood at $279.5 million as of December 31, 2025.
- For 2026, PacBio initiated guidance projecting revenue between $165 million and $180 million, a Non-GAAP Gross Margin of 41% to 44%, and Non-GAAP Operating Expenses of less than $230 million.
Feb 12, 2026, 10:00 PM
PacBio Reports Q4 and Full Year 2025 Results, Provides 2026 Outlook
PACB
Earnings
Guidance Update
Product Launch
- PacBio reported Q4 2025 revenue of $44.6 million, a 14% year-over-year increase, contributing to a full year 2025 revenue of $160 million, up 4% from 2024.
- Consumable revenue reached a record $21.6 million in Q4 2025, growing 15% year-over-year, driven by a 55% growth in consumables for clinical and hospital customers in 2025.
- Non-GAAP gross margin improved significantly to 40% for both Q4 and full year 2025, with an anticipated further improvement of 100-400 basis points in 2026.
- For 2026, the company forecasts revenue between $165 million and $180 million, representing approximately 8% growth at the midpoint, with the launch of SparkNex chemistry expected to improve economics and throughput.
Feb 12, 2026, 10:00 PM
PacBio Announces Fourth Quarter and Full Year 2025 Financial Results
PACB
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- PacBio reported total revenue of $44.6 million for the fourth quarter of 2025, marking a 14% increase year-over-year, and $160.0 million for the full year 2025.
- The company recorded a GAAP net loss of $40.4 million, or $0.13 per basic share, for Q4 2025, compared to a GAAP net income of $2.4 million, or $0.01 per basic share, in Q4 2024. For the full year 2025, the GAAP net loss was $546.4 million, or $1.82 per basic share.
- Consumables revenue reached an all-time record in Q4 2025.
- PacBio completed the sale of short-read sequencing assets for approximately $48.1 million in net cash proceeds, which strengthened its balance sheet.
- The company is preparing for the upcoming launch of SPRQ-Nx, designed to significantly lower sequencing costs.
Feb 12, 2026, 9:10 PM
PacBio Announces Q4 and Full Year 2025 Results
PACB
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- PacBio reported revenue of $44.6 million for the fourth quarter of 2025, marking a 14% year-over-year increase, and full-year 2025 revenue of $160.0 million.
- The company posted a GAAP net loss of $40.4 million for Q4 2025 and a GAAP net loss of $546.4 million for the full year 2025.
- Key operational metrics for Q4 2025 included 21 Revio TM system placements and 42 Vega TM system placements.
- PacBio strengthened its balance sheet by completing the sale of short-read sequencing assets for approximately $48.1 million and is preparing for the upcoming launch of SPRQ-Nx to significantly lower sequencing costs.
Feb 12, 2026, 9:05 PM
Quarterly earnings call transcripts for PACIFIC BIOSCIENCES OF CALIFORNIA.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more